Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Roche Holding AG

Revenue

Target Prices

# of Analysts

Consensus Recommendation

EBITDA

EBIT

Free Cash Flow

FFO / Share

AFFO / Share

NAV / Share

Book Value / Share

CapEx

Estimates	Dec '22 (A)	Dec '23 (A)	Dec '24 (E)
Mean	CHF 63,331.87	CHF 59,501.63	CHF 60,783.29
Median	CHF 63,262.5	CHF 59,121.6	CHF 60,617.23
Actual	CHF 63,281	CHF 58,716	—
High	CHF 65,269	CHF 61,935.03	CHF 62,131.65
Low	CHF 62,060	CHF 58,403.1	CHF 59,200
Standard Deviation	CHF 628.5	CHF 1,080.81	CHF 702.96
# of Estimates	18	14	16

Roche Holding AG

Long Term Revisions Restricted